AlphaCore Pharma's Acquisition

AlphaCore Pharma was acquired by MedImmune on April 04, 2013.

AlphaCore Pharma is developing ACP-501 (rhLCAT) for the treatment of the orphan disease familial LCAT deficiency (FLD) and for the acute treatment of atherosclerosis. In April 2013, AlphaCore Pharma …

Articles about AlphaCore Pharma's Acquisition: